Explore the new section on #EAHADAcademy dedicated to Congress Symposia and access recordings of the symposia presented by CSL and Novo Nordisk. Revisit expert discussions, the latest scientific developments, and practical insights whenever it suits you! 🎥 academy.eahad.org/eahad/?menu=...

Recurrent nosebleeds are often overlooked, but they can be an early sign of Hereditary Hemorrhagic Telangiectasia (HHT). Earlier recognition is key to timely diagnosis and appropriate management. 🎥 Watch our e-learning module featuring Raj S. Kasthuri: academy.eahad.org/eahad/2026/e...

Module 24: Hereditary Hemorrhagic Telangiectasia by Raj S. Kasthuri

EAHAD Academy; Kasthuri R. Jun 10 2026; 4218307;

academy.eahad.org

EAHAD - European Association for Haemophilia and Allied Disorder@eahad.bsky.social · 2mo ago

Hereditary Hemorrhagic Telangiectasia (HHT) affects around 1 in 5,000 people worldwide, yet it remains widely underdiagnosed. Early diagnosis is key to improving outcomes and quality of life for people living with HHT. 🎥 Watch the e-learning module w/ Raj Kasthuri: academy.eahad.org/eahad/2026/e...

Summer is the perfect time to catch up on #Haemophilia education. ☀️ Watch this #EAHAD2026 session on the evolving landscape of factor replacement therapy with Jan Astermark, Annette Bowyer and Cedric Hermans. 🎥 academy.eahad.org/eahad/2026/e...

EAHAD joins EuroBloodNet and @ehc-news.bsky.social for a joint webinar on the latest insights into the global prevalence and ethnic diversity of von Willebrand disease, based on population genetics analysis with Omid Seidizadeh. 📅 10 Sept🔗Register now: eurobloodnet.eu/education/th...

Updated global prevalence and ethnic diversity of von Willebrand disease based on population genetics analysis | ERN-EuroBloodNet Thursdays webinars | Education | EuroBloodNet

eurobloodnet.eu

How long does it really take to recover from a joint bleed? In our latest podcast, we speak with Gijs Aertssen about the factors that influence recovery after a joint bleed and what these findings could mean for everyday clinical practice. 🎧 open.spotify.com/episode/0pFX...

Meet the Author Ep. 11: Predicting Recovery After Joint Bleeding in Persons With Bleeding Disorders

EAHAD · Episode

open.spotify.com

🎥 Missed the EHC #ERIN Webinar on #HaemophiliaB with #Inhibitors? The recording is now available — watch the conversation between clinicians & patient advocates, organised in collaboration with @eahad.bsky.social 👇️ youtu.be/KG3dpFR5V4c?...

ERIN Webinar - Haemophilia B With Inhibitors - From Daily Challenges to Clinical Management

Held on 3 July 2026, this webinar, organised by the European Haemophilia Consortium (EHC) in cooperation with the European Association for Haemophilia and Allied Disorders (EAHAD), brings together…

youtu.be

🔓 Missed the EAHAD–ISTH Joint Session at EAHAD 2026? Last days to catch Guido Giunti as he explores how digital health is transforming the diagnosis and management of bleeding disorders of unknown cause. Relive the insights: academy.eahad.org/eahad/2026/e... 🔓 Free access for one week only

📄 Check the recently published article, which outlines a product-specific operational pathway to support Italian clinicians in managing patients throughout the GT journey and notes that these pathways will evolve as evidence and experience grow: onlinelibrary.wiley.com/doi/10.1111/...

Italian Patients Journey for Gene Therapy in Haemophilia A

Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues rem...

onlinelibrary.wiley.com

🔓 Limited-time open access! The collaboration between EAHAD and @isth brings together international expertise to tackle bleeding disorders of unknown cause with Floor Heubel-Moenen and Guido Giunti. Relive the insights: academy.eahad.org/eahad/2026/e... 🔓 Free access for 1 week only

🎥 Missed our latest Gene Therapy online session or want to rewatch it? The full replay of "Inhibitor Development in Gene Therapy for Haemophilia" is now available on the EAHAD Academy. 🔗 Watch it now: academy.eahad.org/eahad/2026/g... 👀 And stay tuned for our next Gene Therapy webinar!

Hereditary Hemorrhagic Telangiectasia (HHT) affects around 1 in 5,000 people worldwide, yet it remains widely underdiagnosed. Early diagnosis is key to improving outcomes and quality of life for people living with HHT. 🎥 Watch the e-learning module w/ Raj Kasthuri: academy.eahad.org/eahad/2026/e...

Hereditary Hemorrhagic Telangiectasia (HHT) affects around 1 in 5,000 people worldwide, yet it remains widely underdiagnosed. Early diagnosis is key to improving outcomes and quality of life for people living with HHT. 🎥 Watch the e-learning module w/ Raj Kasthuri: academy.eahad.org/eahad/2026/e...

📄Read the new publication on the JTH supported by the EAHAD Research Grants 2024: “Prothrombotic PROC variant rebalancing hemostasis in severe haemophilia A with attenuated bleeding risk”. Congratulations to the authors on this valuable contribution to the field. 🔗 www.jthjournal.org/article/S153...

Prothrombotic PROC variant rebalancing hemostasis in severe hemophilia A with attenuated bleeding risk

Severe hemophilia A (HA), defined by a clotting factor [F]VIII level of <1%, leads to a severe bleeding tendency. A pathogenic F8 variant p.His300Lysfs∗41 accounted for <1% FVIII levels in a patient w...

jthjournal.org

Last few hours to register for our upcoming webinar on Inhibitor Development in Gene Therapy for Haemophilia ⏳ Join Yesim Dargaud, Davide Matino, Sébastien Lacroix-Desmazes, and Guy Young as they explore emerging insights in the field 🧬 🔗 Register now: academy.eahad.org/eahad/2026/g...

⏳ Final Call! Join our upcoming webinar on Inhibitor Development in Gene Therapy for Haemophilia with Yesim Dargaud, Davide Matino, Sebastien Lacroix-Desmazes, Guy Young to explore these key issues. 📅 Monday | 17:00 CEST 🔗 Register now: academy.eahad.org/eahad/2026/g...

Missed the Novo Nordisk symposium on Refocusing on haemophilia B: Patient-centric approaches to using anti-TFPI at EAHAD 2026? The full session is now available on the EAHAD Academy. Replay the session: academy.eahad.org/eahad/2025/n...

🎥 Watch the new e-learning module featuring Raj S. Kasthuri on Hereditary Hemorrhagic Telangiectasia (HHT) to review the genetic basis, pathophysiology, clinical manifestations, diagnostic criteria, and current management strategies for HHT: academy.eahad.org/eahad/2026/e...

The Request for Proposals to host the Annual EAHAD Congress 2030 is now open! This is your chance to put your city in the spotlight and contribute to advancing care for patients across Europe. 🌍 Visit the EAHAD website for submission guidelines: www.eahad.org/request-for-... 🗓️ Deadline: 1 Jan 2027

Request for Proposals (RFP) to Host Annual EAHAD Congress 2030

Are you a clinician actively involved in the haemophilia and bleeding disorders field and a dedicated member of EAHAD? If so, we're happy to inform you that we've just launched the EAHAD 2030 Request ...

eahad.org

Are there identifiable patterns or risk factors emerging from real-world cases? Discuss the topic in our upcoming Gene Therapy webinar, which brings together expert perspectives from Yesim Dargaud, Davide Matino, Sébastien Lacroix-Desmazes, and Guy Young. 🔗 academy.eahad.org/eahad/2026/g...

EAHAD - European Association for Haemophilia and Allied Disorder@eahad.bsky.social · 3mo ago

🧬 What do clinical trial data suggest about the long-term relevance of inhibitors in treated patients? Register for our upcoming webinar to hear expert discussion on emerging clinical data. 📅 15 June | 17:00 CEST 🔗 academy.eahad.org/eahad/2026/g...

📰 New real-world data from the Adelphi Real World Haemophilia Disease Specific Programme underline persistent unmet needs in haemophilia and the continued challenge of aligning treatment outcomes with patient priorities 🔗 @haemophilia_jnl onlinelibrary.wiley.com/doi/10.1111/...

Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database

Introduction Prophylactic factor replacement and non-factor therapy has improved bleed prevention and clinical outcomes for people with haemophilia (PwH). The remaining burdens faced by PwH in real-.....

onlinelibrary.wiley.com

📣 EAHAD and @ehc-news.bsky.social come together once again, bringing together clinical perspectives, patient experiences, and interactive discussion to support a deeper understanding of Haemophilia B with inhibitors. Register now 🔗https://form.dragnsurvey.com/survey/r/b5590c21

Which patient- or treatment-related factors influence immune activation after gene transfer? Join Yesim Dargaud, Davide Matino, Sébastien Lacroix-Desmazes, and Guy Young for an expert discussion 🔗https://academy.eahad.org/eahad/2026/gene-therapy-in-haemophilia-2026

EAHAD - European Association for Haemophilia and Allied Disorder@eahad.bsky.social · 3mo ago

🧬 What do clinical trial data suggest about the long-term relevance of inhibitors in treated patients? Register for our upcoming webinar to hear expert discussion on emerging clinical data. 📅 15 June | 17:00 CEST 🔗 academy.eahad.org/eahad/2026/g...

🎥 Watch the new e-learning module featuring Johanna Gebhart and Yesim Dargaud, and explore the diagnostic challenges behind unexplained bleeding, complex laboratory assessment strategies, and practical considerations for clinical management: academy.eahad.org/eahad/2026/e...

EAHAD - European Association for Haemophilia and Allied Disorder@eahad.bsky.social · 3mo ago

How many patients are still living with a bleeding disorder diagnosis that remains unexplained? BDUC and ultra-rare bleeding disorders continue to represent some of the most complex and under-recognised challenges in haemostasis care. 🎥 Learn more on EAHAD Academy: academy.eahad.org/eahad/2026/e...

The EAHAD von Willebrand Disease WG has launched a new survey to assess the availability of diagnostic tools and treatment options across European medical centres. We invite healthcare professionals to contribute their experience and insights. Take part here: lnkd.in/eJuCHntY

🧬 What do clinical trial data suggest about the long-term relevance of inhibitors in treated patients? Register for our upcoming webinar to hear expert discussion on emerging clinical data. 📅 15 June | 17:00 CEST 🔗 academy.eahad.org/eahad/2026/g...

How many patients are still living with a bleeding disorder diagnosis that remains unexplained? BDUC and ultra-rare bleeding disorders continue to represent some of the most complex and under-recognised challenges in haemostasis care. 🎥 Learn more on EAHAD Academy: academy.eahad.org/eahad/2026/e...

The Late-Breaking session at EAHAD 2026 brought the latest data first! Discover new interim and long-term results on emerging therapies. 🎥 Missed the live session? Relive the insights anytime on EAHAD Academy: academy.eahad.org/eahad/2026/e... 🔒 For EAHAD Members only

📄 Check out the graphical summary of the recently published NEJM Group article on Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. A clear visual overview of the latest clinical data and key findings shaping the evolving haemophilia treatment landscape.

Gene therapy is transforming the treatment landscape of haemophilia, but major questions remain regarding its use in patients with current or past inhibitors. Join our next Gene Therapy webinar on 15 June @ 17:00 CEST! Register now: academy.eahad.org/eahad/2026/g...

What does occupational therapy look like in haemophilia care today, and where is it heading? Listen to Claire Forde discussing how the occupational therapy service was established and evolved. 🎧 Listen now: open.spotify.com/episode/6Zu5...